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Introduction. Posttransplantation allosensitization prevalence and effect on kidney grafts outcomes remain unsettled. Methods.
Between 2007 and 2012, 408 patients received a primary kidney graft (with 68 patients also receiving a pancreas graft) after a negative
cytotoxic crossmatch. All patients had a pretransplant negative anti-HLA screening and 0% panel reactive antibodies. We analyzed
retrospectively the results of anti-HLA antibodies screening by Luminex assay, performed between 6 and 24months after transplant,
and searched for the risk factors for antibody positivity and its impact on kidney graft outcomes. Results. Anti-HLA antibodies
prevalence at 6 months was 17.4%. Previous steroid-insensitive acute rejection was the only risk factor for both anti-HLA classes
detected antibodies. Antithymocyte globulin induction was also a risk factor for anti-HLA-I antibodies. Antibody positivity status
was associatedwith reduced graft function at 12months and graft survival at 5 years (91.5% versus 96.4%,𝑃 = 0.03). Inmultivariable
Cox analysis, delayed graft function (HR= 6.1, 𝑃 < 0.01), HLA mismatches >3 (HR= 10.2, 𝑃 = 0.03), and antibody positivity for
anti-HLA class II (HR= 5.1, 𝑃 = 0.04) or class I/II (HR= 13.8, 𝑃 < 0.01) were independent predictors of graft loss. Conclusions.
Allosensitization against HLA class II ± I after transplant was associated with adverse kidney graft outcomes. A screening protocol
seems advisable within the first year in low immunological risk patients.
1. Introduction
Unsensitized kidney and kidney-pancreas recipients may
develop de novo antibodies against human leukocyte antigens
(HLA) after transplantation. Posttransplantation allosensiti-
zation prevalence is still disputed, since it depends among
other factors on the method used for anti-HLA antibodies
detection [1]. For instance, the use of less sensitive techniques
such as complement-dependent cytotoxicity (CDC) cross-
match assays in comparison with more sensitive methods as
solid-phase assays will result in lower rates of sensitization
[2].This explains that published prevalence of anti-HLA anti-
bodies detected after kidney transplantation ranges from 1.6
to 60% [1]. Uncertainty of the detection of de novo anti-HLA
antibodiesmay also result from the use of inaccuratemethods
to define pretransplant sensitization status.Historical reliance
on CDC panel-reactive antibody (PRA) likely missed anti-
HLA antibodies present at the time of transplant [3].
Several factors have been associated with the develop-
ment of de novo anti-HLA antibodies such as higher number
of HLA mismatches [4, 5], younger recipient age [5], and
previous acute rejection episodes [4]. Hourmant et al. [6]
showed that previous acute rejection was associated with the
development of de novo anti-HLA antibodies, donor-specific
or not. Besides the clear etiopathogenic connection between
anti-HLA antibodies presence and antibody-mediated rejec-
tion (AMR), earlier acute cellular rejection (ACR) episodes
have also been associated with development of de novo anti-
HLA antibodies [4, 7].
The deleterious effect of de novo anti-HLA antibodies
detection on graft outcomes has been demonstrated [1].
A prospective study designed to evaluate the relationship
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between anti-HLA antibodies development at 1-year after
transplant and kidney graft loss showed that antibody-
positive recipients had a significantly higher incidence of
graft loss after 1-year follow-up [8]. This has led many trans-
plant centers to implement anti-HLA antibodies screening
protocols after transplantation, although the target pop-
ulation for these protocols remains matter of discussion
[9].
Thus, we decided to analyze in a cohort of low immuno-
logical risk patients the relationship between de novo anti-
HLA antibodies detected at 6-month after transplant and
kidney graft outcomes. Accordingly, we selected for analysis
only patients without allosensitization before transplant as
determined by CDC PRA and/or a screening by Luminex
solid-phase assay. An association between anti-HLA antibod-
ies detection and significant graft outcomes would support
the clinical usefulness of this screening strategy in low risk
patients.
2. Material and Methods
2.1. Subjects. We retrospectively analyzed 579 adult patients
who received a first kidney (𝑛 = 498) or a kidney-
pancreas (𝑛 = 81) transplant between 2007 and 2012, with
a functioning kidney graft for at least 6 months, and in
whom a CDC PRA test and anti-HLA antibodies screening
had been performed before transplant. All antibody-positive
patients underwent LABScreen test for detection of anti-HLA
antibodies around the 6th month after transplant. Antibody-
negative patients were selected if they had a negative screen-
ing performed between the 6th and the 24thmonth following
transplant; in patients with multiple screenings only those
with negative results in all of them were selected. We used
stringent criteria to select patients without pretransplant
allosensitization in order to analyze its prevalence and effect
after transplantation. Hence, we considered only primary
graft recipients and we excluded patients with a pretransplant
(historical or current) CDC PRA > 0% and/or a positive
anti-HLA antibodies screening (𝑛 = 161) and patients with
positive screening posttransplant after a negative one at 6
months (𝑛 = 10), defining the remaining 408 patients as
the study population. All patients were transplanted with
a negative pretransplant T- and B-lymphocyte cytotoxicity
crossmatch.
The Institutional Review Board at Centro Hospitalar do
Porto approved this study.
2.2. Anti-HLA Screening and % PRA. CDC PRA test was
performed before transplant in all patients with sera col-
lected every 3 months while in waiting list, using total
peripheral blood lymphocytes collected from a HLA-typed
representative donor population. It was considered positive
if cell lyses remained present after dithiothreitol (DTT)
treatment, identifying only IgG anti-HLA isotypes positive
cases.
Pre- and posttransplant anti-HLA IgG antibodies were
tested by multiplex microsphere based flow cytometry
(Luminex Technology, LABScreen Mixed kit, OneLambda,
Canoga Park, CA). Color-coded microspheres, coated with
the major HLA class I and II antigens, were incubated with
the serum for 30min at room temperature in the dark. After
three washes the samples were incubated with 100 𝜇L of
1 : 100 phycoerythrin-conjugated goat antihuman IgG (One
Lambda Inc.). Finally, after two washes, the fluorescent
signal intensity for each microsphere was measured using
LABScan 100 Flow analyzer (One Lambda Inc.). The cutoff
for positive samples was the normalized background (NBG)
ratio recommended by the manufacturer and performed by
the HLA fusion software (One Lambda).
In deceased donor recipients, no flow cytometry cross-
match was performed since patients had a CDC PRA = 0%
and no detectable anti-HLA antibodies before transplant.
Flow cytometric crossmatch was performed in living donor
recipients as standard practice (all transplants were carried
out with a negative T- and B-cell flow crossmatch).
2.3. Pretransplant Induction Protocol and Maintenance Imm-
unosuppression. Induction therapy was used in 370 patients
(90.7%), with 256 patients receiving an anti-IL-2 receptor
monoclonal antibody (basiliximab, 20mg twice at day 0
and 4) and 114 patients receiving polyclonal antithymocyte
globulin (ATG Fresenius, 3mg/kg for 5–7 days). Per pro-
tocol, kidney-pancreas recipients (𝑛 = 68) received ATG
for induction, with only 4 patients receiving basiliximab
instead. ATG was used in kidney-only recipients at the
clinician discretion, mainly due to a high number of HLA
mismatches. All enrolled recipients had similar triple main-
tenance immunosuppression, consisting of oral tacrolimus
(FK-506), mycophenolate mofetil (MMF), and methylpred-
nisolone (MP)/prednisolone. FK-506 was started at the dose
of 0.1–0.15mg/kg/day, and the dose was adjusted to maintain
a trough level of FK-506 in whole blood between 8 and
12 ng/mL during the first month postoperatively, between 7
and 10 ng/mLduring 2-3months after transplant andbetween
5 and 8 ng/mL thereafter. MMF was started at the dose of
2000mg/day, with the dose decreasing to 1000–1500mg/day
during the first month postoperatively, depending on white
blood cells count. Methylprednisolone was administered
intravenously at doses of 500, 250, and 125mg/day on the day
of transplantation, on day 1-2 and day 3-4 after the operation,
respectively. Oral prednisolone was started on day 5 after
the operation at the dose of 20mg, being then tapered to 5–
10mg/day within 2-3 months after transplant. Living donor
recipients (𝑛 = 76) were prescribed FK-506 and MMF 7 days
before transplant.
2.4. Data Analysis and Outcomes. Data regarding recipient
and donor characteristics and pre- and posttransplanta-
tion variables were collected retrospectively in all patients.
Delayed graft function was defined as dialysis requirement in
the first week after transplant. Estimated glomerular filtration
rate (eGFR) was evaluated at 12 months after transplant
in patients with a functioning graft at that moment (𝑛 =
404), using the 2006 MDRD equation. Graft survival was
analyzed considering graft failure censored for death with a
functioning graft.
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2.5. Rejection Diagnosis and Treatment. Allograft rejection
was defined as biopsy proven rejection (specimens were eval-
uated by light microscopy and immunofluorescence staining
for C4d) and classified according to Banff classification as
updated in 2007. Mild acute cellular rejection (ACR Banff
grade I) was treated with pulse steroids (500mg MP for
3 days) and increased maintenance immunosuppression.
All other ACR episodes were treated with ATG. Antibody-
mediated rejection (AMR) was also treated with pulse
steroids and intravenous immunoglobulin 2 g/kg (maximum
140 g) divided in two doses associated with plasmapheresis
(at least 3–5 sessions). Acute rejection episodes were further
classified as steroid-sensitive rejections (ACR Banff grade I)
or steroid-insensitive rejections (ACR Banff grade II and III
and AMR).
2.6. Statistical Analysis. Continuous datawas described using
mean (standard deviation) or median (interquartile range)
and categorical data was expressed as number (frequencies).
Demographic, clinical, and immunological features and post-
transplant anti-HLA antibodies status were compared using
Pearson chi-square test or Fisher’s exact test for categorical
data and Student’s 𝑡-test orMann-Whitney𝑈 test for continu-
ous data, as appropriate. Logistic regression analysis was used
to determine significant associations between studied vari-
ables and 6-month presence of anti-HLA antibodies, using
a multivariable model that included variables presenting 𝑃 ≤
0.1 in univariable analysis (ATGuse, time on dialysis, kidney-
pancreas graft, acute rejection type, recipient age, donor age,
and ABDR mismatches) (data not shown). Graft survival
curves were visualized using Kaplan-Meier method, with in-
between groups comparison done by log-rank test. Univari-
able andmultivariable Cox proportional hazards analysis was
applied to assess independent predictors of censored graft
failure; a multivariable model (including variables presenting
𝑃 ≤ 0.1 in univariable analysis: ATG use, recipient age,
donor age, delayed graft function, ABDR mismatches, and
anti-HLA antibodies screen) was constructed to adjust for
potential confounders.
A two-sided 𝑃 value < 0.05 was considered as statistically
significant. Statistical calculations were performed using
SPSS for Mac, version 20.0 (SPSS Inc., Chicago, IL, USA).
3. Results
In our cohort of 408 unsensitized kidney and kidney-
pancreas recipients, anti-HLA antibodies were detected at 6-
month after transplant in 71 patients (17.4%), with 49 (12.0%)
being positive for anti-HLA class I, 12 (2.9%) for anti-HLA
class II, and 10 (2.5%) for anti-HLA class I and II antibodies.
Median follow-up was 44 months (interquartile range: 31–
60).
3.1. Baseline Characteristics and Variables Associated with
the Presence of Anti-HLA Antibodies (Table 1). Patients with
detectable anti-HLA antibodies were significantly younger,
had a younger donor, and were predominantly kidney-
pancreas recipients.They had a significant higher mean HLA
mismatches and underwent induction immunosuppression
with ATG more frequently. At 6 months after transplant,
occurrence of previous acute rejection was more common in
patients with detectable anti-HLA antibodies. No significant
difference was found in delayed graft function prevalence.
A multivariable logistic regression analysis was per-
formed to determine risk factors for anti-HLA antibodies
positivity at 6 months (Table 2). Steroid-insensitive acute
rejection episodes were a potent risk factor (OR = 6.47, 𝑃 <
0.01) for anti-HLA antibodies presence of any class. Steroid-
sensitive acute rejection episodes were marginally associated
(OR = 3.90, 𝑃 = 0.05) with anti-HLA class II detection.
Remarkably, ATG induction was a risk factor (OR = 4.04,
𝑃 < 0.01) for anti-HLA class I detection.
3.2. Acute Rejection Characteristics and Anti-HLA Antibodies
Detection. Forty-four patients had acute rejection in the first
6 months after transplant, with 22 rejections being classified
as ACR grade I, 17 as ACR grade II, and 5 as AMR (2 of them
had also ACR grade I and 1 had also ACR grade II). Previous
AMR and ACR grade II episodes were more frequent in
patients with detectable anti-HLA antibodies than in those
without them [AMR: 4 (5.6%) versus 1 (0.3%) 𝑃 < 0.01; ACR
grade II: 6 (8.5%) versus 11 (3.3%) 𝑃 = 0.047]. Differently,
ACR grade I occurrencewas similar between groups [5 (7.0%)
versus 17 (5.0%), 𝑃 = 0.50]. No significant difference was
detected in acute rejection between patients with andwithout
ATG induction (7.9% versus 11.9%, resp., 𝑃 = 0.24).
3.3. Anti-HLA Antibodies and Kidney Graft Outcomes after
Antibody Testing. At 12 months after transplant, antibody-
positive recipients had a significantly lower mean eGFR
than antibody-negative patients (48.5 ± 20.1 and 54.0 ±
18.1mL/min, resp., 𝑃 = 0.04).
After 5-year follow-up, 6 (8.5%) antibody-positive recip-
ients lost their grafts, while this occurred in only 12 (3.6%)
of antibody-negative patients (Figure 1). When we analyzed
antibody positivity accordingly to HLA class, censored graft
loss was associated with the presence of anti-HLA class II
(2 patients lost their graft) or anti-HLA class I/II (3 patients
lost their graft), but not with the presence of anti-HLA class
I (1 patient lost his graft) antibodies only (Figure 2). Of the
18 patients with graft failure, graft biopsies obtained between
antibody testing and failure were available in 10 patients
(8 from antibody-positive and 2 from antibody-negative
patients). In antibody-positive patients, 6 presented a grade
II/III and 2 patients a grade I interstitial fibrosis and tubular
atrophy according to Banff ’07 classification; simultaneously
5 patients had signs of chronic active antibody-mediated
rejection without C4d deposition (peritubular capillaries
and/or glomerular inflammation) and 4 patients presented
with mild to moderate interstitial infiltration. In antibody-
negative patients, 1 biopsy showed a grade I interstitial fibrosis
and tubular atrophy together with mild interstitial infiltra-
tion; the other specimen presented no significant changes.
Kidney graft loss occurred in 16 (4.7%) kidney-only and
in 2 (2.9%) kidney-pancreas graft recipients (𝑃 = 0.75).
Given the association of ATG induction with anti-HLA class
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Table 1: Baseline characteristics and events at 6-months posttransplant for all patients and between anti-HLA (−) and anti-HLA (+) antibodies
groups.
Variables All patients
𝑁 = 408
anti-HLA (−)
𝑁 = 337
anti-HLA (+)
𝑁 = 71
𝑃 value
Recipient variables
Age (years), mean ± SD 43.5 ± 15.2 44.4 ± 14.7 39.1 ± 17.2 0.02
Female gender, 𝑛 (%) 133 (32.6%) 105 (31.2%) 28 (39.4%) 0.18
Time on dialysis (mo), median (IQR) 41.0 (17.4–74.3) 41.8 (17.9–75.1) 28.4 (10.9–53.8) 0.06
Previous blood transfusions, 𝑛 (%) 130 (31.9%) 107 (31.8%) 23 (32.4%) 0.92
Females with previous pregnancies, 𝑛 (%) 56 (42.1%) 47 (44.8%) 9 (32.1%) 0.29
KP recipients, 𝑛 (%) 68 (16.7%) 50 (14.8%) 18 (25.4%) 0.03
Donor variables
Age (years), mean ± SD 44.5 ± 15.6 45.8 ± 14.7 38.3 ± 18.3 <0.01
Female gender, 𝑛 (%) 143 (35.0%) 117 (34.7%) 26 (36.6%) 0.82
Living donor, 𝑛 (%) 76 (18.6%) 65 (19.3%) 11 (15.5%) 0.46
Transplantation variables
ABDR HLA mismatches, mean ± SD 3.89 ± 1.41 3.82 ± 1.43 4.21 ± 1.25 0.02
ABDR mismatches >3, 𝑛 (%) 261 (64.0%) 211 (62.6%) 50 (70.4%) 0.21
Cold ischemia time (h), median (IQR) 14.7 (10–18.2) 14 (9.5–18) 16.5 (11–19) 0.91
Induction therapy
ATG use, 𝑛 (%) 114 (27.9%) 81 (24.0%) 33 (46.5%) <0.01
Basiliximab use, 𝑛 (%) 256 (62.7%) 222 (65.9%) 34 (48.6%) 0.01
No induction, 𝑛 (%) 38 (9.3%) 34 (10.1%) 4 (5.6%) 0.37
Posttransplant events at 6-mo
Blood transfusions, 𝑛 (%) 29 (7.1%) 22 (6.5%) 7 (9.9%) 0.31
Delayed graft function, 𝑛 (%) 73 (17.9%) 58 (17.2%) 15 (21.1%) 0.43
Acute rejection, 𝑛 (%) 44 (10.8%) 29 (8.6%) 15 (21.1%) <0.01
Steroid-sensitive, 𝑛 (%) 22 (5.4%) 17 (5.0%) 5 (7.0%) 0.50
Steroid-insensitive, 𝑛 (%) 22 (5.4%) 12 (3.5%) 10 (14.1%) <0.01
HLA: human leukocyte antigen; SD: standard deviation; mo: months; IQR: interquartile range; KP: kidney-pancreas; h: hours; ATG: anti-thymocyte globulin.
I positivity, we analyzed graft survival considering induction
therapy used. Most graft losses occurred in patients without
induction therapy or induced with basiliximab (𝑛 = 16). In
patients induced with ATG (𝑛 = 114) only 2 lost their grafts
(none from the antibody-positive group).
Furthermore, a Cox proportional hazard model was con-
structed to explore predictors of censored graft loss (Table 3).
In the multivariable analysis, anti-HLA class II or anti-HLA
class I/II antibodies positivity, delayed graft function and
HLA ABDR mismatches > 3 were significant predictors of
censored graft loss.
3.4. Patient Deaths after Antibody Testing. Six patients died
during follow-up, 5 (death causes: neoplasia 2, cardiovascular
disease 2, and septicemia 1) in the antibody-negative group
and 1 (from septicemia) in the antibody-positive group (𝑃 =
1.0).
4. Discussion
In our cohort of kidney and kidney-pancreas recipients
without pretransplant allosensitization, anti-HLA antibodies
positive screening at 6 months was associated with worse
kidney graft function and survival. Prevalence of de novo anti-
HLA antibodies was 17.4%, being anti-HLA class I in 69%,
anti-HLA class II in 17%, and against both classes in 14% of
antibody-positive patients. Similar results were reported in
kidney and kidney-pancreas recipients in whom alloantibody
analysis was performed by solid-phase assays. In one study
[7] of 277 patients (77% kidney and 23% kidney-pancreas
recipients), 21.8% of those without allosensitization before
transplantation became allosensitized at a mean 2.6 years
after transplant, against HLA class II in the majority of cases.
Forty patients from a cohort of 167 pancreas graft recipients
with 91% receiving simultaneously a kidney graft (7 patients
wereHLA-sensitized before transplant) had a positive screen-
ing for anti-HLA antibodies at a median follow-up of 1-year,
with detected antibodies equally distributed between HLA
classes (47.5% for each, with 5% positive for both) [10]. Our
cohort presented a lower prevalence of HLA-sensitization,
probably due to its low immunological risk character and an
earlier done antibody screening.
We acknowledge that anti-HLA class I antibodies high
prevalence in our population is in contrast with published
data in which anti-HLA class II predominates within de
novo anti-HLA antibodies [4, 5, 11], but most of these
studies analyzed only donor-specific anti-HLA antibodies
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Table 2: Risk factors for anti-HLA antibodies positivity at 6 months
by multivariable∗ logistic regression analysis.
Odds ratio 95% IC 𝑃 value
Risk factors for anti-HLA (+)
ATG use 3.05 1.49–6.25 <0.01
Acute rejection
No episode Reference
Steroid-sensitive 1.75 0.59–5.16 0.31
Steroid-insensitive 6.47 2.55–16.42 <0.01
Risk factors for anti-HLA
class I (+)
ATG use 4.04 1.89–8.65 <0.01
Acute rejection
No episode Reference
Steroid-sensitive 1.05 0.29–3.87 0.94
Steroid-insensitive 4.45 1.63–12.09 <0.01
Risk factor for anti-HLA
class II (+)
Acute rejection
No episode Reference
Steroid-sensitive 3.90 0.99–15.42 0.05
Steroid-insensitive 5.05 1.46–17.46 0.01
∗Variables included in the model are ATG use, time on dialysis, kidney-
pancreas graft, acute rejection type, recipient age, and donor age, ABDR
mismatches.
HLA: human leukocyte antigen; IC: confidence interval; ATG: antithymo-
cyte globulin.
prevalence, without mention to overall anti-HLA antibodies
prevalence and had a longer median follow-up to antibody
detection (at least 17 months). Additionally, we found an
independent association between induction therapy with
ATG and positivity for anti-HLA class I antibodies at 6
months, also reported by others authors [6, 12]. This associa-
tion cannot be attributed solely to amore frequent use of ATG
induction in recipients with a higher immunological risk,
since it remained significant in a multivariable regression
model that included variables related with allosensitization
risk (HLA mismatches, kidney-pancreas transplantation). In
a case control study [12] that included two groups of patients
well matched for immunological risk variables but differing
in the use of ATG induction, a significant increase (over
10%) of anti-HLA class I antibodies after transplant, using
a FlowPRA solid-phase assay, was observed more frequently
in ATG induced patients than in those without induction
therapy (22.2% versus 0%; 𝑃 = 0.02). Hourmant et al. [6],
reporting in a population of 1229 kidney graft recipients (10%
also received a pancreas graft), found a prevalence of 16.8%
anti-HLA antibodies at a mean follow-up of around 6 years
using a ELISA screening test. Antibody-positive patients had
received more frequently induction with ATG (76% versus
58%; 𝑃 < 0.01). No information is given about against which
class (I and/or II) were the detected anti-HLA antibodies.The
main issue here is if this association results from a laboratory
interference of a xeno-antibody present in ATG preparation
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Figure 1: Graft survival censored for death with a functioning
graft according to anti-HLA antibodies presence at 6 months
after transplant. Antibody-positive patients (𝑛 = 71) showed a
significantly lower survival rate at 5 years than antibody-negative
patients (𝑛 = 337) (91.5% versus 96.4%, resp., log-rank test 𝑃 =
0.03).
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Figure 2: Graft survival censored for death with a functioning graft
according to presence of anti-HLA antibodies against class I, class
II, or class I/II at 6 months after transplant. Patients with antibody
positivity for class II (𝑛 = 12) (83.3%, log-rank test𝑃 = 0.02) or class
I/II (𝑛 = 10) (70%, log-rank test 𝑃 < 0.01) showed a significantly
lower survival rate at 5 years than antibody-negative patients (𝑛 =
337). Graft survival was similar in antibody-negative patients and
those positive only for class I (𝑛 = 49) anti-HLA antibodies (96.4%
versus 98% resp., log-rank test 𝑃 = 0.76).
[13] with no foreseeable effect on the graft or if it results
from an imbalance between T- and B-cell populations with a
stronger depletion effect in the former (including regulatory
T-cells) allowing for humoral responses to evolve [14]. Our
results are in accordance with the first proposition, since we
reported only 2 graft losses in the ATG induced group and no
significant difference was detected in acute rejection between
patients with and without ATG induction. High frequency
of positivity for anti-HLA class I antibodies in our cohort is
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Table 3: Predictors of censored kidney graft loss by Cox proportional hazard analysis.
Hazard ratio 95% IC 𝑃-value
Univariable analysis
Recipient age 1.05 1.01–1.08 0.01
Male (versus female) recipient 0.58 0.23–1.46 0.26
Living (versus deceased) donor 0.04 0.01–5.87 0.20
Donor age 1.03 0.99–1.07 0.07
Male (versus female) donor 0.48 0.19–1.25 0.13
Delayed graft function 5.85 2.30–14.85 <0.01
ATG use 0.30 0.07–1.29 0.10
ABDR HLA mismatches >3 9.39 1.25–70.60 0.03
Time on dialysis ≥48 (versus <48)mo 2.05 0.79–5.28 0.14
Acute rejection
No episode Reference
Steroid-sensitive 1.17 0.15–8.83 0.88
Steroid-insensitive 2.02 0.46–8.86 0.35
Kidney-pancreas recipient 0.62 0.14–2.72 0.53
Anti-HLA antibodies at 6mo after transplant
Negative Reference
Class I 0.71 0.09–5.46 0.74
Class II 4.79 1.07–21.40 0.04
Class I + II 10.95 3.08–38.96 <0.01
Multivariable analysis∗
Recipient age 1.02 0.98–1.07 0.29
Donor age 1.02 0.98–1.06 0.45
ATG use 0.44 0.09–2.06 0.30
Delayed graft function 6.11 2.21–16.92 <0.01
ABDR HLA mismatches >3 10.17 1.32–78.55 0.03
Anti-HLA antibodies at 6mo after transplant
Negative Reference
Class I 1.23 0.15–10.11 0.85
Class II 5.12 1.07–24.53 0.04
Class I + II 13.79 3.41–55.77 <0.01
∗Variables included in the model are ATG use, recipient age, donor age, delayed graft function, ABDR mismatches, and anti-HLA antibodies screen.
IC: confidence interval; ATG: antithymocyte globulin; mo: months; HLA: human leukocyte antigen.
probably associated with the precociousness of our antibody
screening in relation to ATG use, not only as induction
therapy but also in the treatment of the steroid-insensitive
acute rejections episodes (𝑛 = 22).
Acute rejection episodes, if classified as vascular ACR or
AMR (steroid-insensitive), were a strong risk factor for anti-
HLA antibodies detection, independently of HLA class. In
kidney-pancreas recipients, it has been shown that vascular
(Banff grade II or III) kidney graft ACR was significantly
more common in patients with posttransplant detection of
anti-HLA antibodies [10]. Recently, a retrospective study in
2079 kidney-only graft recipients recognized that cases of
vascular ACR should be reevaluated if simultaneous presence
of donor-specific anti-HLA antibodies was detected [15].
With their reevaluation, more than a half of the cases
formerly classified as vascular ACR would be reclassified as
vascular AMR, an entity that presented particularly poor
graft outcomes. An association of ACR and later development
of de novo anti-HLA antibodies may relate with the degree
of microcirculatory inflammation present at the time of
the ACR, in particular the sensitizing effect of upregulated
HLA proteins expression in the peritubular capillaries [16].
Moreover, histopathological analysis of vascular rejection
biopsies showed that concomitant presence of peritubular
capillaritis was very common (around 90%) [17]. We found
no significant association between the number of HLA mis-
matches and appearance of anti-HLA antibodies in themulti-
variable logistic analysis, in spite of a significant higher HLA
mismatches mean in antibody-positive recipients. Lachmann
et al. [18] found no significant difference between ABDR
mismatches mean and posttransplant antibody screening
status. Others [4, 19] found HLA mismatches number to be
associated with de novo donor-specific anti-HLA antibodies,
particularly for HLA-DR mismatches.
The lack of information regarding specificities of the
detected antibodies, namely the recognition of donor-specific
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antibodies, represents a limitation of this study. Never-
theless, we found that anti-HLA antibody detection was
a significant predictor of kidney graft outcome, as it was
associated with lower eGFR at 1-year posttransplant and with
reduced censored graft survival at 5-year follow-up. When
anti-HLA antibodies class was considered, we detected that
only antibodies against class II or class I/II were significant
predictors of censored graft failure. A multivariable Cox
analysis confirmed these results, besides identifying delayed
graft function and a higher number of HLA mismatches as
other predictors of graft failure. Several studies after 2000,
using the solid-phase assays, have demonstrated anti-HLA
antibodies presence to be a significant predictor of poorer
graft survival [6, 20]. De novo posttransplant detection of
alloantibodies in kidney and kidney-pancreas recipients was
associated with a significantly lower death censored graft
survival [7]. More recently, with the development of single
antigen beads technology the emphasis has been put in the
role of de novo donor-specific anti-HLA antibodies. Several
studies show that anti-HLA antibodies detrimental effect
on graft survival is restricted to de novo donor-specific
antibodies [4, 21, 22]. Interestingly, it has been shown in
a cohort of kidney-pancreas patients that the significant
detrimental impact of anti-HLA antibodies on kidney graft
outcome (death-censored graft survival at 9-years was 53% in
anti-HLA positive and 89% in anti-HLA negative patients)
was due to donor-specific antibodies, since patients with
anti-HLA antibodies non-donor-specific and those anti-HLA
negative had similar graft survival (92% versus 89%) [10].
Additionally, they showed that although anti-HLA antibodies
were equally distributed between HLA classes, when they
analyzed antibody-positive patients, with or without donor-
specific antibodies, antibodies anti-HLA class II predom-
inated in the former and anti-HLA class I in the latter.
Nonetheless, others have demonstrated poorer graft survival
associated with anti-HLA antibodies irrespective of donor
specificity [6, 23]. Colleagues fromCharite´ Hospital in Berlim
[18] screened kidney graft recipients (11% also received a
pancreas) at amedian of 5 years after transplantwith Luminex
solid-phase assays for anti-HLA antibodies presence. Patients
with detectable anti-HLA antibodies had significantly worse
graft survival than those that remained unsensitized (63%
versus 83%) at 5.5-year follow-up.When kidney graft survival
analysis was stratified for anti-HLA antibodies presence and
their specificities, they found that both donor-specific (49%)
and non-donor-specific antibodies (70%) were associated
with worse graft survival than antibody-negative patients
(83%). They also reported that eGFR at time of antibody
testing was significantly lower in antibody-positive patients.
Graft histopathological data from available biopsies of
patients with eventual censored graft failure displayedmild to
moderate chronic damage pattern, frequently associated with
presence of inflammatory lesions, recognized as both cellular
and antibody-mediated. All graft failures in antibody-positive
patients occurred at least 1 year after antibody testing, further
underlining the indolent nature of the processes at play.
An independent detrimental effect on kidney graft survival
(through loss by chronic rejection) of anti-HLA antibodies
development within 1 year after transplantation has been
reported [24]. Campos et al. [25] showed that the presence
of anti-HLA class II antibodies (alone or concomitant with
class I) was a predictor of graft loss due to chronic allograft
nephropathy, independently from the degree of renal func-
tion decline already observed at the time of antibody testing.
The definition of our cohort as low immunological risk
may be criticized given the inclusion of kidney-pancreas
patients, althoughwe have shown that double transplantation
was not an independent risk factor for antibody positivity
nor was it associated with higher graft loss. The different
timing for the evaluation of anti-HLAantibodies (at 6months
in antibody-positive and between 6 and 24 months after
transplant in antibody-negative patients) may be disputed.
However, we believe that the exclusion of every patient with a
positive screening after the 6-month screening minimizes it.
Our results about the relevance of anti-HLA antibodies
screening at 6 months after transplant should be carefully
assessed. We describe a probable laboratorial interference
with the detection of anti-class I HLA antibodies associated
with ATG use that renders those results clinically irrelevant.
We were unable to determine the precise time interval
between ATG use and antibody testing. Probably, a screening
done at 12 months after transplant would allow us to surpass
it. Nevertheless, a significant association between a positive
screening for anti-class II±I HLA antibodies and kidney
graft adverse outcomes was found. Naturally, a positive
screening should prompt clinicians to perform an assay for
identification of antibody specificities in order to define
eventual donor specificity.
5. Conclusions
We recommend caution in the interpretation of positive
screening for anti-HLA antibodies against class I in patients
that recently received ATG therapy. Nonetheless, our results
show that anti-HLA antibodies screening after transplant
should be a tool in the clinical management of patients with
low immunological risk. It is a first step in the study of
allosensitization, identifying those in need of more accurate
but also more expensive assays, thus allowing for a more
adequate allocation of means. A screening protocol for
detection of de novo allosensitizationwithin the first year after
transplant seems advisable for most transplanted patients.
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